View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 7, 2021updated 11 Jul 2022 2:22pm

Vaxart starts subject enrolment in trial of oral vaccine for Covid-19

Approximately 96 subjects in the US will be given the vaccine as part of the trial this month. 

Vaxart has commenced participant recruitment in the Phase II clinical trial of S-only oral tablet vaccine candidate for Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

This month, the company expects to start dosing the first of 96 US volunteers categorised equally between Covid 19 naïve and messenger ribonucleic acid (mRNA) vaccinated participants.

The Phase II Covid-19 programme will also be conducted outside of the US. In the initial stage, a trial is expected to be launched in India later this year.

Vaxart founder and chief scientific officer Dr Sean Tucker said: “We’re very excited to start Phase II trials of our S-only vaccine candidate because in our nonhuman primate studies, our S-only vaccine produced much higher serum antibody levels than the S+N construct did.

“Vaxart’s new trials will generate key data that will allow us to compare the S-only and S+N vaccine candidates and help us decide on the best development path forward for our Covid 19 vaccine programme, particularly in the face of emerging variant strains.”

The company’s vaccines are created to be used as tablets that require no refrigeration for storage and shipping.

Vaxart CEO Andrei Floroiu said: “An oral vaccine has the potential to dramatically impact the world’s response to the Covid 19 pandemic and to improve global public health.

“It can be easier and faster to administer than injectables and can help mitigate vaccine hesitancy, as many of those unwilling to get vaccinated by needle would take an oral tablet vaccine.”

Vaxart’s tablet vaccine delivery platform can potentially offer recombinant vaccines, aiding the company to create oral formulations of presently sold vaccines and to develop recombinant vaccines for novel indications.

At present, the development programmes of the company comprise tablet vaccines to offer protection against coronavirus, seasonal influenza, norovirus and respiratory syncytial virus (RSV).

Vaxart is also developing a therapeutic human papillomavirus (HPV) vaccine.

In September last year, Vaxart received clearance from the US Food and Drug Administration to conduct a Phase I trial of its Covid 19 vaccine candidate.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena